Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation
Open Access
- 9 May 2013
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 13 (1) , 231
Abstract
Background: Aggressive neuroblastoma remains a significant cause of childhood cancer death despite current intensive multimodal treatment protocols. The purpose of the present work was to characterize the genetic and clinical diversity of such tumors by high resolution arrayCGH profiling. Methods: Based on a 32K BAC whole-genome tiling path array and using 50-250K Affymetrix SNP array platforms for verification, DNA copy number profiles were generated for 34 consecutive high-risk or lethal outcome neuroblastomas. In addition, age and MYCN amplification (MNA) status were retrieved for 112 unfavorable neuroblastomas of the Swedish Childhood Cancer Registry, representing a 25-year neuroblastoma cohort of Sweden, here used for validation of the findings. Statistical tests used were: Fisher’s exact test, Bayes moderated t-test, independent samples t-test, and correlation analysis. Results: MNA or segmental 11q loss (11q-) was found in 28/34 tumors. With two exceptions, these aberrations were mutually exclusive. Children with MNA tumors were diagnosed at significantly younger ages than those with 11q- tumors (mean: 27.4 vs. 69.5 months; p=0.008; n=14/12), and MNA tumors had significantly fewer segmental chromosomal aberrations (mean: 5.5 vs. 12.0; pMYCN. Knowledge on such nosological diversity of aggressive neuroblastoma might influence future strategies for therapy.Keywords
This publication has 34 references indexed in Scilit:
- Response, survival, and toxicity after iodine‐131–metaiodobenzylguanidine therapy for neuroblastoma in preadolescents, adolescents, and adultsCancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Accumulation of Segmental Alterations Determines Progression in NeuroblastomaJournal of Clinical Oncology, 2010
- Recent Advances in NeuroblastomaNew England Journal of Medicine, 2010
- Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q− NeuroblastomaClinical Cancer Research, 2010
- High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onsetProceedings of the National Academy of Sciences, 2010
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: Four cases of homozygous deletions of the CDKN2A geneBMC Genomics, 2008
- Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray ExperimentsStatistical Applications in Genetics and Molecular Biology, 2004
- Cytogenetic evolution of mycn and mdm2 amplification in the neuroblastoma ls tumour and its cell lineEuropean Journal of Cancer, 1995